SCHEMBL8049902

SCHEMBL8049902

COC(=O)c1nc2c(NC(C)C3CCCCC3)ncnc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPS6KB1 P23443 1/20 0.50
▸ LDHA P00338 1/20 0.40
▸ LDHB P07195 1/20 0.40
▸ OPRK1 P41145 1/20 0.36
▸ RIPK1 Q13546 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ CSF1R P07333 1/20 0.36
▸ P2RX7 Q99572 1/20 0.35
▸ MAPK1 P28482 3/20 0.35
▸ EGFR P00533 1/20 0.34
▸ HIF1A Q16665 2/20 0.34
▸ CA12 O43570 2/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33
▸ MMP2 P08253 2/20 0.33
▸ CA9 Q16790 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8053837 0.79 RPS6KB1 (0.47) RPS6KB1LDHALDHBJAK2JAK1
SCHEMBL8057106 0.78 RPS6KB1 (0.47) RPS6KB1LDHALDHBJAK2JAK1
SCHEMBL8051613 0.76 RPS6KB1 (0.45) RPS6KB1LDHALDHBJAK3CSF1R
SCHEMBL4958934 0.70 RIPK1 (0.35) OPRK1RIPK1MAPK1ALDH1A1NPSR1
SCHEMBL10256310 0.67 RPS6KB1 (1.00) RPS6KB1
SCHEMBL666702 0.67 RPS6KB1 (1.00) RPS6KB1
SCHEMBL1609224 0.64 PDE10A (0.43) RPS6KB1LDHALDHBOPRK1P2RX7
SCHEMBL15354441 0.63 MAP4K4 (0.46) JAK2EGFRALDH1A1NPSR1
SCHEMBL11153637 0.62 NPC1 (0.56) MAPK1ALDH1A1
SCHEMBL15889091 0.62 MAP4K4 (0.39) EGFRALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1999045016-A9 NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS METABASIS THERAPEUTICS INC (US) 2000-03-02 — — WO disclosed
Send feedback